Abrinica, Clyde .
HRN: 27-22-75 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/24/2025
CEFTAZIDIME 1GM (VIAL)
09/24/2025
10/01/2025
IV
385mg
Q8h
PCAP C
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes